Compare Coupang Inc (CPNG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Merck & Co., Inc. — how do they compare? Coupang Inc trades at $17.49 (market cap $32.17B), while Merck & Co., Inc. trades at $123.63 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 9.3× Coupang Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Coupang Inc pays none. Which is the better fit depends on your goals.
| CPNG | MRK | |
|---|---|---|
Market Cap | $32.17B | $298.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.53 | $129.52 |
52-Week Low | $15.12 | $77.60 |
Enterprise Value | $31.26B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPNG trades at $17.92, down 4.68% today, with a bearish technical signal and mixed earnings. Revenue grew to $34.53B in 2025, but net income margin is negative at -0.47%. Recent news includes a $412M fine for a data breach in South Korea (Reuters, 2026-06-11). The stock faces regulatory headwinds but maintains strong analyst support with an 87.5% buy rating and a $25.80 consensus target.
Outlook: CPNG offers growth potential from e-commerce expansion but carries risks from regulatory fines and profitability challenges. Investors should weigh strong cash flow against recent earnings misses and legal issues. The stock's current price is 30% below the consensus target, presenting upside if execution improves.
Merck (MRK) trades at $123.52, down 0.41% on the day, amid a bullish technical signal and strong institutional interest. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives. Valuation ratios include a P/E of 34.02 and P/S of 4.58, while cash flow from operations remains healthy at $16.47B in 2025.
The outlook for MRK is positive, driven by earnings beats, a dominant oncology portfolio, and analyst consensus favoring buys. Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06 in 2025, and competitive pressures in the pharmaceutical sector. The stock offers potential upside to the consensus price target of $137.30, but investors should monitor execution risks from recent acquisitions and macroeconomic factors affecting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
